首页> 美国卫生研究院文献>BMJ Open Gastroenterology >Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
【2h】

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)

机译:非酒精性脂肪性肝纤维化(NASF)可以独立预测非酒精性脂肪性肝病(NAFLD)患者的死亡率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundHepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) independently predicts mortality. Given liver biopsy’s invasive nature, non-invasive method to assess hepatic steatosis and fibrosis provides NAFLD risk stratification algorithm in clinical practice. NAFLD fibrosis score (NFS) is simple and non-invasive predictive model recommended by American Association for the Study of Liver Disease (AASLD) Guideline to identify patients with NAFLD with fibrosis risk. The aim of this study is to assess long-term outcomes of subjects with significant non-alcoholic steatofibrosis (NASF) as established by ultrasound (US) and NFS.
机译:背景非酒精性脂肪肝疾病(NAFLD)患者的肝纤维化独立预测死亡率。考虑到肝活检的侵入性,评估肝脂肪变性和纤维化的非侵入性方法在临床实践中提供了NAFLD风险分层算法。 NAFLD纤维化评分(NFS)是美国肝病研究协会(AASLD)指南推荐的简单且非侵入性的预测模型,用于识别患有纤维化风险的NAFLD患者。这项研究的目的是评估由超声(US)和NFS确定的患有严重非酒精性脂肪性纤维化(NASF)的受试者的长期预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号